An Engineered Human-Antibody Fragment with Fentanyl Pan-Specificity That Reverses Carfentanil-Induced Respiratory...

Area of Science:

• Pharmacology
• Immunology
• Drug Discovery

Background:

• The synthetic opioid crisis has caused over 500,000 US deaths in 20 years.
• Naloxone is the current short-acting opioid overdose treatment, but alternatives are needed to prevent renarcotization.

Purpose of the Study:

• To develop a novel therapeutic countermeasure against potent synthetic opioids, specifically carfentanil.
• To generate and characterize a fully human monoclonal antibody with broad specificity for opioid analogs.

Main Methods:

• Utilized a drug-specific B cell sorting strategy with carfentanil and fentanyl probes.
• Employed scFv phage display for antibody optimization, yielding C10-S66K.
• Determined X-ray crystal structures of drug:antibody complexes.

Main Results:

• Developed C10-S66K, a pan-specific monoclonal antibody with high affinity for carfentanil, fentanyl, and related analogs.
• Demonstrated that C10-S66K effectively reversed carfentanil-induced respiratory depression in preclinical models.
• Obtained structural insights into the drug:antibody interactions critical for high-affinity binding.

Conclusions:

• The fully human monoclonal antibody C10-S66K represents a promising new therapeutic strategy for reversing synthetic opioid overdoses.
• Structural data provides a foundation for further development of opioid-specific antibody therapeutics.
• This approach offers a potential solution to prevent renarcotization following opioid overdose treatment.